{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T13:35:07Z","timestamp":1762522507590,"version":"build-2065373602"},"reference-count":17,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.japh.2020.08.028","type":"journal-article","created":{"date-parts":[[2020,9,16]],"date-time":"2020-09-16T02:24:57Z","timestamp":1600223097000},"page":"1037-1043.e3","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["HCV eradication in veterans with underlying mental health disorders and substance use"],"prefix":"10.1016","volume":"60","author":[{"given":"Amanda P.","family":"Ifeachor","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kelly K.","family":"Houck","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Samantha","family":"Schulte","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9835-0305","authenticated-orcid":false,"given":"Elayne","family":"Ansara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew J.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas A.","family":"Carr","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Suthat","family":"Liangpunsakul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.japh.2020.08.028_bib4","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1056\/NEJMp1716871","article-title":"Hepatitis C in injection-drug users - a hidden danger of the opioid epidemic","volume":"378","author":"Liang","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"2","key":"10.1016\/j.japh.2020.08.028_bib5","doi-asserted-by":"crossref","first-page":"175","DOI":"10.2105\/AJPH.2017.304132","article-title":"Increases in acute hepatitis C virus infection related to a growing opioid epidemic and associated injection drug use, United States, 2004 to 2014","volume":"108","author":"Zibbell","year":"2018","journal-title":"Am J Public Health"},{"issue":"6","key":"10.1016\/j.japh.2020.08.028_bib6","doi-asserted-by":"crossref","first-page":"893","DOI":"10.2105\/AJPH.2017.303748","article-title":"Restrictions of hepatitis C treatment for substance-using Medicaid patients: cost versus ethics","volume":"107","author":"Liao","year":"2017","journal-title":"Am J Public Health"},{"issue":"1","key":"10.1016\/j.japh.2020.08.028_bib7","doi-asserted-by":"crossref","first-page":"76","DOI":"10.5604\/01.3001.0010.7537","article-title":"Recreational drug and psychosocial profile in chronic hepatitis C patients seeking antiviral therapy","volume":"17","author":"George","year":"2018","journal-title":"Ann Hepatol"},{"issue":"12","key":"10.1016\/j.japh.2020.08.028_bib8","doi-asserted-by":"crossref","first-page":"2695","DOI":"10.1093\/cid\/ciz693","article-title":"Low hepatitis C reinfection following direct-acting antiviral therapy among people who inject drugs on opioid agonist therapy","volume":"70","author":"Akiyama","year":"2020","journal-title":"Clin Infect Dis"},{"issue":"3","key":"10.1016\/j.japh.2020.08.028_bib9","doi-asserted-by":"crossref","first-page":"215","DOI":"10.7326\/M15-0406","article-title":"Restrictions for Medicaid reimbursement of sofosbuvir for the treatment of hepatitis C virus infection in the United States","volume":"163","author":"Barua","year":"2015","journal-title":"Ann Intern Med"},{"issue":"12","key":"10.1016\/j.japh.2020.08.028_bib11","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1097\/MEG.0b013e3283624a28","article-title":"A\u00a0novel program for treating patients with trimorbidity: hepatitis C, serious mental illness, and active substance use","volume":"25","author":"Sockalingam","year":"2013","journal-title":"Eur J Gastroenterol Hepatol"},{"year":"2019","series-title":"Pegasys [Package Insert]","key":"10.1016\/j.japh.2020.08.028_bib12"},{"issue":"1","key":"10.1016\/j.japh.2020.08.028_bib13","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1002\/hep.30171","article-title":"Has access to hepatitis C virus therapy changed for patients with mental health or substance use disorders in the direct-acting-antiviral period?","volume":"69","author":"Jain","year":"2019","journal-title":"Hepatology"},{"author":"Negro","key":"10.1016\/j.japh.2020.08.028_bib16"},{"key":"10.1016\/j.japh.2020.08.028_bib20","doi-asserted-by":"crossref","first-page":"103208","DOI":"10.1016\/j.jbi.2019.103208","article-title":"REDCap Consortium: building an international community of software platform partners","volume":"95","author":"Harris","year":"2019","journal-title":"J\u00a0Biomed Inform"},{"author":"Grebely","key":"10.1016\/j.japh.2020.08.028_bib22"},{"issue":"11","key":"10.1016\/j.japh.2020.08.028_bib23","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1176\/appi.ps.201700542","article-title":"Why Me?\" understanding the HCV care continuum among people with serious mental illness","volume":"69","author":"Arnold","year":"2018","journal-title":"Psychiatr Serv"},{"issue":"6","key":"10.1016\/j.japh.2020.08.028_bib24","doi-asserted-by":"crossref","first-page":"1469","DOI":"10.1007\/s10620-012-2141-4","article-title":"Time to rethink antiviral treatment for hepatitis C in patients with coexisting mental health\/substance abuse issues","volume":"57","author":"Bonner","year":"2012","journal-title":"Dig Dis Sci"},{"issue":"10","key":"10.1016\/j.japh.2020.08.028_bib25","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.drugpo.2019.07.016","article-title":"International Network on Hepatitis in Substance Users. Elimination of hepatitis C virus infection among people who use drugs: ensuring equitable access to prevention, treatment, and care for all","volume":"72","author":"Grebely","year":"2019","journal-title":"Int J Drug Policy"},{"issue":"5","key":"10.1016\/j.japh.2020.08.028_bib26","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.japh.2019.05.003","article-title":"Pharmacist-driven multidisciplinary pretreatment workup process for hepatitis C care: a novel model for same-day pretreatment workup","volume":"59","author":"Houck","year":"2019","journal-title":"J\u00a0Am Pharm Assoc (2003)"},{"issue":"11","key":"10.1016\/j.japh.2020.08.028_bib27","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1016\/j.cgh.2015.02.022","article-title":"Integrated care increases treatment and improves outcomes of patients with chronic hepatitis C virus infection and psychiatric illness or substance abuse","volume":"13","author":"Ho","year":"2015","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319120304398?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319120304398?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:52:03Z","timestamp":1761544323000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319120304398"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S1544319120304398"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2020.08.028","relation":{},"ISSN":["1544-3191"],"issn-type":[{"type":"print","value":"1544-3191"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HCV eradication in veterans with underlying mental health disorders and substance use","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2020.08.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Published by Elsevier Inc. on behalf of the American Pharmacists Association.","name":"copyright","label":"Copyright"}]}}